Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 8/20 | 0.60 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.59 |
| ▸ | YARS1 | P54577 | 2/20 | 0.56 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | CPA1 | P15085 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7149294 | 1.00 | MME (0.60) | MMESLC7A5YARS1ACECPA1 | |
| SCHEMBL30326195 | 1.00 | MME (0.60) | MMESLC7A5YARS1ACECPA1 | |
| SCHEMBL30287990 | 0.96 | MME (0.60) | MMESLC7A5YARS1ACECPA1 | |
| SCHEMBL30287993 | 0.96 | MME (0.60) | MMESLC7A5YARS1ACECPA1 | |
| SCHEMBL31025679 | 0.96 | MME (0.60) | MMESLC7A5YARS1ACECPA1 | |
| Water SCHEMBL7150501 | 0.96 | MME (0.56) | MMESLC7A5YARS1ACECPA1 | |
| SCHEMBL30788342 | 0.94 | MME (0.54) | MMESLC7A5YARS1ACECPA1 | |
| SCHEMBL30288033 | 0.92 | MME (0.66) | MMEACEOPRD1 | |
| SCHEMBL30288011 | 0.92 | MME (0.66) | MMEACEOPRD1 | |
| SCHEMBL30288043 | 0.92 | MME (0.66) | MMEACEOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024161169-A1 | ACROSS BLOOD BRAIN BARRIER DELIVERY OF TOLL-LIKE RECEPTORS LIGANDS AND THERAPIES THEREOF | BIOASIS TECHNOLOGIES, INC. (CA) | 2024-08-08 | — | — | WO | claimed |
| EP-4157358-A1 | COMPOSITIONS AND METHODS FOR TREATING FRONTOTEMPORAL DEMENTIA | biOasis Technologies Inc. (CA) | 2023-04-05 | — | — | EP | claimed |
| EP-4132563-A1 | COMPOSITIONS AND METHODS FOR TREATING LEWY BODY DEMENTIA | biOasis Technologies Inc. (CA) | 2023-02-15 | — | — | EP | claimed |
| CN-105407907-A | Uric acid level lowering agent | SUNTORY HOLDINGS LTD | 2016-03-16 | — | — | CN | claimed |
| EP-4634396-A1 | BIOBASED SYNTHESIS OF GLUCODIAMINE | Solugen, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| WO-2025076549-A1 | SMALL MOLECULE ACTIVATORS | SOLUGEN, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2024161169-A1 | ACROSS BLOOD BRAIN BARRIER DELIVERY OF TOLL-LIKE RECEPTORS LIGANDS AND THERAPIES THEREOF | BIOASIS TECHNOLOGIES, INC. (CA) | 2024-08-08 | — | — | WO | disclosed |
| WO-2024129887-A1 | BIOBASED SYNTHESIS OF GLUCODIAMINE | SOLUGEN, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20230399374-A1 | Compounds, Compositions and Methods of Use to Treat Bone Fractures | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-12-14 | — | — | US | disclosed |
| CN-116801900-A | Compounds, compositions and methods of use for treating bone fractures | 普渡研究基金会 | 2023-09-22 | — | — | CN | disclosed |
| EP-4232074-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT BONE FRACTURES | Purdue Research Foundation (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-110075315-B | Antibody conjugate, and preparation method and application thereof | 上海复旦张江生物医药股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| EP-0866684-A1 | COSMETIC HAIR TREATMENT METHOD | UNILEVER PLC (GB) | 1998-09-30 | — | — | EP | disclosed |
| WO-1997022329-A1 | COSMETIC HAIR TREATMENT METHOD | UNILEVER PLC (GB) | 1997-06-26 | — | — | WO | disclosed |
| EP-0457701-B1 | Derivatives of endogenous mediators, their salts, process for preparation, application and compositions containing them | IMMUNOTECH SA (FR) | 1995-02-22 | — | — | EP | disclosed |
| US-5298491-A | Derivatives of endogenous mediators, their salts, method of preparation, applications and compositions in which they are present | IMMUNOTECH (FR) | 1994-03-29 | — | — | US | disclosed |
| EP-0457701-A1 | Derivatives of endogenous mediators, their salts, process for preparation, application and compositions containing them | IMMUNOTECH S.A. (FR) | 1991-11-21 | — | — | EP | disclosed |
| EP-0145386-B1 | DERIVATIZED POLYSTYRENE AND OTHER POLYMER SUPPORTS FOR SPECTROSCOPIC STUDIES | CITY OF HOPE NATIONAL MEDICAL CENTER (US) | 1991-05-15 | — | — | EP | disclosed |
| US-4978724-A | Method of preparing derivatized polystyrene for spectroscopic studies | APPLIED IMMUNESCIENCES, INC. (US) | 1990-12-18 | — | — | US | disclosed |
| EP-0145386-A2 | Derivatized polystyrene and other polymer supports for spectroscopic studies | CITY OF HOPE NATIONAL MEDICAL CENTER (US) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399374-A1 | Compounds, Compositions and Methods of Use to Treat Bone Fractures | SOST, BMP2, BMP4 | MME 630/4885SLC7A5 3739/4885YARS1 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.